Pharmacological topics of bone metabolism

Recent advances in pharmacological management of osteoporosis

Atsushi Suzuki, Sahoko Sekiguchi, Shogo Asano, Mitsuyasu Itoh

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The prevention of osteoporotic fracture is an essential socioeconomical priority, especially in the developed countries including Japan. Estrogen, selective estrogen-receptor modulators (SERMs), and bisphosphonate are potent inhibitors of bone resorption; and they have clinical relevance to reduce osteoporotic fractures in postmenopausal women. However, we can prevent at most 50% of vertebral fractures with these agents. For the better compliance of aminobisphosphonate, the use of a daily bisphosphonate regimen is moving to a weekly or monthly bisphosphonate regimen. Both cathepsin K inhibitors and modulators of the RANK-RANKL system, which can reduce bone resorption, are the candidates for the future treatment of osteoporosis. As well as bone resorption, we need to increase bone formation to prevent osteoporotic fractures, particularly in elderly patients with low bone turnover. In the U.S., Europe, and Australia, they have already started intermittent parathyroid hormone injection and/ or oral strontium ranelate to stimulate bone formation. We still need to discover new agents to reduce osteoporotic fractures for the better quality of life without fractures.

Original languageEnglish
Pages (from-to)530-535
Number of pages6
JournalJournal of Pharmacological Sciences
Volume106
Issue number4
DOIs
Publication statusPublished - 24-04-2008

Fingerprint

Osteoporotic Fractures
Osteoporosis
Diphosphonates
Pharmacology
Bone and Bones
strontium ranelate
Bone Resorption
Osteogenesis
Cathepsin K
Bone Density Conservation Agents
Selective Estrogen Receptor Modulators
Bone Remodeling
Parathyroid Hormone
Developed Countries
Compliance
Japan
Estrogens
Quality of Life
Injections
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

@article{6c9adbe8882b42e4a639808309b02aad,
title = "Pharmacological topics of bone metabolism: Recent advances in pharmacological management of osteoporosis",
abstract = "The prevention of osteoporotic fracture is an essential socioeconomical priority, especially in the developed countries including Japan. Estrogen, selective estrogen-receptor modulators (SERMs), and bisphosphonate are potent inhibitors of bone resorption; and they have clinical relevance to reduce osteoporotic fractures in postmenopausal women. However, we can prevent at most 50{\%} of vertebral fractures with these agents. For the better compliance of aminobisphosphonate, the use of a daily bisphosphonate regimen is moving to a weekly or monthly bisphosphonate regimen. Both cathepsin K inhibitors and modulators of the RANK-RANKL system, which can reduce bone resorption, are the candidates for the future treatment of osteoporosis. As well as bone resorption, we need to increase bone formation to prevent osteoporotic fractures, particularly in elderly patients with low bone turnover. In the U.S., Europe, and Australia, they have already started intermittent parathyroid hormone injection and/ or oral strontium ranelate to stimulate bone formation. We still need to discover new agents to reduce osteoporotic fractures for the better quality of life without fractures.",
author = "Atsushi Suzuki and Sahoko Sekiguchi and Shogo Asano and Mitsuyasu Itoh",
year = "2008",
month = "4",
day = "24",
doi = "10.1254/jphs.FM0070218",
language = "English",
volume = "106",
pages = "530--535",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8613",
publisher = "Japanese Pharmacological Society",
number = "4",

}

Pharmacological topics of bone metabolism : Recent advances in pharmacological management of osteoporosis. / Suzuki, Atsushi; Sekiguchi, Sahoko; Asano, Shogo; Itoh, Mitsuyasu.

In: Journal of Pharmacological Sciences, Vol. 106, No. 4, 24.04.2008, p. 530-535.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacological topics of bone metabolism

T2 - Recent advances in pharmacological management of osteoporosis

AU - Suzuki, Atsushi

AU - Sekiguchi, Sahoko

AU - Asano, Shogo

AU - Itoh, Mitsuyasu

PY - 2008/4/24

Y1 - 2008/4/24

N2 - The prevention of osteoporotic fracture is an essential socioeconomical priority, especially in the developed countries including Japan. Estrogen, selective estrogen-receptor modulators (SERMs), and bisphosphonate are potent inhibitors of bone resorption; and they have clinical relevance to reduce osteoporotic fractures in postmenopausal women. However, we can prevent at most 50% of vertebral fractures with these agents. For the better compliance of aminobisphosphonate, the use of a daily bisphosphonate regimen is moving to a weekly or monthly bisphosphonate regimen. Both cathepsin K inhibitors and modulators of the RANK-RANKL system, which can reduce bone resorption, are the candidates for the future treatment of osteoporosis. As well as bone resorption, we need to increase bone formation to prevent osteoporotic fractures, particularly in elderly patients with low bone turnover. In the U.S., Europe, and Australia, they have already started intermittent parathyroid hormone injection and/ or oral strontium ranelate to stimulate bone formation. We still need to discover new agents to reduce osteoporotic fractures for the better quality of life without fractures.

AB - The prevention of osteoporotic fracture is an essential socioeconomical priority, especially in the developed countries including Japan. Estrogen, selective estrogen-receptor modulators (SERMs), and bisphosphonate are potent inhibitors of bone resorption; and they have clinical relevance to reduce osteoporotic fractures in postmenopausal women. However, we can prevent at most 50% of vertebral fractures with these agents. For the better compliance of aminobisphosphonate, the use of a daily bisphosphonate regimen is moving to a weekly or monthly bisphosphonate regimen. Both cathepsin K inhibitors and modulators of the RANK-RANKL system, which can reduce bone resorption, are the candidates for the future treatment of osteoporosis. As well as bone resorption, we need to increase bone formation to prevent osteoporotic fractures, particularly in elderly patients with low bone turnover. In the U.S., Europe, and Australia, they have already started intermittent parathyroid hormone injection and/ or oral strontium ranelate to stimulate bone formation. We still need to discover new agents to reduce osteoporotic fractures for the better quality of life without fractures.

UR - http://www.scopus.com/inward/record.url?scp=42349096158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42349096158&partnerID=8YFLogxK

U2 - 10.1254/jphs.FM0070218

DO - 10.1254/jphs.FM0070218

M3 - Article

VL - 106

SP - 530

EP - 535

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8613

IS - 4

ER -